Skip to main content

COVID Can Threaten Sickle Cell Patients, But Too Few Are Vaccinated

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 12, 2024.

By Dennis Thompson HealthDay Reporter

FRIDAY, Jan. 12, 2024 -- Sickle cell disease is one of many chronic health conditions that dramatically increases the risk of hospitalization and death in people infected by COVID-19.

Unfortunately, folks with sickle cell disease are much less likely to have received the best protection available to them -- a COVID vaccine.

Completion of the initial two-dose COVID vaccination series is nearly two times lower for adults with sickle cell disease compared to others their age, according to a report published Jan. 8 in the journal JAMA Network Open.

The rates are even lower than that for children younger than 18, researchers say.

For the study, the team analyzed Michigan state data from sickle cell and immunization registries. In all, they had records for more than 3,400 people ages 5 and older with sickle cell disease to compare against data on 9.4 million other state residents over age 5.

About 61% of Michigan residents without sickle cell disease had completed at least the primary series of COVID vaccine by August 2022, researchers found.

But only 34% of those with sickle cell disease had gotten themselves fully vaccinated, results show.

The highest-risk group, those over 65, had the highest vaccination rates – 74% for sickle cell patients compared to 87% for the general population.

However, there were only 110 people with sickle cell disease in that age range, partially due to the fact that the condition tends to cause people to die early, the researchers said.

Vaccination rates were even lower in children and teens with sickle cell disease, who have a higher rate of hospitalization and death if they are infected with COVID.

Only 17% of kids ages 5 to 11 and 31% of those ages 12 to 17 with sickle cell disease had gotten the primary series of COVID vaccine, compared with 25% and 41% of the general population in those age groups.

"It is essential to develop targeted interventions to increase COVID-19 vaccination among people with sickle cell disease," said researcher Sarah Reeves, an assistant professor of epidemiology and pediatrics with the University of Michigan School of Public Health.

"This population is chronically underserved in healthcare and society, emphasizing the importance of increasing the accessibility and acceptability of these vaccines," Reeves added in a university news release.

Sources

  • University of Michigan, news release, Jan. 8, 2024

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted January 2024

Further Support and Information on COVID-19

Read this next

Extended Course of Paxlovid Adds No Benefit for Those With Long COVID

FRIDAY, June 7, 2024 -- An extended course of the antiviral drug Paxlovid won’t ease a person’s Long COVID symptoms, a new study finds. People who took Paxlovid for...

FDA Panel OKs New COVID Vaccine for Fall

THURSDAY, June 6, 2024 -- A U.S. Food and Drug Administration advisory panel on Wednesday recommended updating the formula for COVID vaccines ahead of a fall campaign that will...

Long COVID's Toll Outlined in New Report

THURSDAY, June 6, 2024 -- Long COVID continues to plague millions of Americans as the health costs of the pandemic linger four years later, a new report warns. In a hefty...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.